Published in Radiology on February 12, 2009
Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther (2012) 3.25
Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology (2011) 3.08
In vivo characterization of the liver fat ¹H MR spectrum. NMR Biomed (2010) 3.07
Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology (2011) 2.42
T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging (2011) 2.27
The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol (2010) 2.05
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology (2014) 2.00
Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging (2012) 1.90
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology (2013) 1.78
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology (2013) 1.77
Identification of brown adipose tissue in mice with fat-water IDEAL-MRI. J Magn Reson Imaging (2010) 1.73
Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obesity (Silver Spring) (2009) 1.70
Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology (2015) 1.60
Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther (2015) 1.54
Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice. Radiology (2010) 1.53
Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am (2010) 1.51
Chemical shift-based water/fat separation: a comparison of signal models. Magn Reson Med (2010) 1.50
Addressing phase errors in fat-water imaging using a mixed magnitude/complex fitting method. Magn Reson Med (2011) 1.41
Assessment of liver fat quantification in the presence of iron. Magn Reson Imaging (2010) 1.30
Assessment of abdominal adipose tissue and organ fat content by magnetic resonance imaging. Obes Rev (2011) 1.27
Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology (2012) 1.23
Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging (2011) 1.14
Independent estimation of T*2 for water and fat for improved accuracy of fat quantification. Magn Reson Med (2010) 1.13
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One (2012) 1.10
Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol (2014) 1.10
Validation of MRI biomarkers of hepatic steatosis in the presence of iron overload in the ob/ob mouse. J Magn Reson Imaging (2011) 1.08
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol (2016) 1.06
On the performance of T2* correction methods for quantification of hepatic fat content. Magn Reson Med (2011) 1.03
Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology (2014) 1.02
Multipeak fat-corrected complex R2* relaxometry: theory, optimization, and clinical validation. Magn Reson Med (2013) 1.02
MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends. Quant Imaging Med Surg (2013) 1.00
Robustness of fat quantification using chemical shift imaging. Magn Reson Imaging (2011) 0.99
Reproducibility of MR-based liver fat quantification across field strength: Same-day comparison between 1.5T and 3T in obese subjects. J Magn Reson Imaging (2015) 0.98
Fatty liver deposition and sparing: a pictorial review. Insights Imaging (2011) 0.97
Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol (2013) 0.96
Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol (2011) 0.95
Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2*-corrected, spectrum-modeled MRI. J Magn Reson Imaging (2013) 0.94
Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis. J Magn Reson Imaging (2013) 0.94
Comparison of R2* correction methods for accurate fat quantification in fatty liver. J Magn Reson Imaging (2012) 0.94
Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J Magn Reson Imaging (2013) 0.94
Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. Hepatology (2015) 0.94
Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis. Hepatology (2013) 0.93
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J (2013) 0.92
Startup circuit training program reduces metabolic risk in Latino adolescents. Med Sci Sports Exerc (2011) 0.92
Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging (2011) 0.92
Adipose tissue MRI for quantitative measurement of central obesity. J Magn Reson Imaging (2012) 0.91
Fat deposition decreases diffusion parameters at MRI: a study in phantoms and patients with liver steatosis. Eur Radiol (2012) 0.90
Noise analysis for 3-point chemical shift-based water-fat separation with spectral modeling of fat. J Magn Reson Imaging (2010) 0.89
Cross-sectional investigation of correlation between hepatic steatosis and IVIM perfusion on MR imaging. Magn Reson Imaging (2012) 0.88
Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract (2013) 0.88
Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women. Eur Radiol (2015) 0.88
Quantification of hepatic steatosis with dual-energy computed tomography: comparison with tissue reference standards and quantitative magnetic resonance imaging in the ob/ob mouse. Invest Radiol (2012) 0.87
On the confounding effect of temperature on chemical shift-encoded fat quantification. Magn Reson Med (2013) 0.87
Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach. Eur Radiol (2013) 0.86
Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging (2014) 0.86
Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery. BMC Med (2014) 0.85
Liver fat volume fraction quantification with fat and water T1 and T 2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T. Eur Radiol (2013) 0.85
Effect of echo-sampling strategy on the accuracy of out-of-phase and in-phase multiecho gradient-echo MRI hepatic fat fraction estimation. J Magn Reson Imaging (2013) 0.85
Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults. Abdom Imaging (2015) 0.84
Liver steatosis: concordance of MR imaging and MR spectroscopic data with histologic grade. Radiology (2012) 0.84
Fat confounds the observed apparent diffusion coefficient in patients with hepatic steatosis. Magn Reson Med (2012) 0.83
Intramuscular fat in ambulant young adults with bilateral spastic cerebral palsy. BMC Musculoskelet Disord (2014) 0.82
Magnetic Resonance Elastography and Other Magnetic Resonance Imaging Techniques in Chronic Liver Disease: Current Status and Future Directions. Gut Liver (2016) 0.82
Accuracy of multiecho magnitude-based MRI (M-MRI) for estimation of hepatic proton density fat fraction (PDFF) in children. J Magn Reson Imaging (2015) 0.82
No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med (2016) 0.81
MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjects. PLoS One (2014) 0.81
Quantitative MRI for hepatic fat fraction and T2* measurement in pediatric patients with non-alcoholic fatty liver disease. Pediatr Radiol (2014) 0.80
Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol (2015) 0.80
Longitudinal Changes in Liver Fat Content in Asymptomatic Adults: Hepatic Attenuation on Unenhanced CT as an Imaging Biomarker for Steatosis. AJR Am J Roentgenol (2015) 0.80
Quantification of liver fat with respiratory-gated quantitative chemical shift encoded MRI. J Magn Reson Imaging (2015) 0.80
Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. Abdom Imaging (2015) 0.79
Accuracy of Liver Fat Quantification With Advanced CT, MRI, and Ultrasound Techniques: Prospective Comparison With MR Spectroscopy. AJR Am J Roentgenol (2016) 0.79
Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and intralipid solutions and correlation to insulin levels. Metabolism (2013) 0.79
Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One (2014) 0.79
Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease. World J Gastroenterol (2015) 0.79
Sensitivity of chemical shift-encoded fat quantification to calibration of fat MR spectrum. Magn Reson Med (2015) 0.79
Effect of hepatocyte-specific gadolinium-based contrast agents on hepatic fat-fraction and R2(⁎). Magn Reson Imaging (2014) 0.78
Age- and Gender Dependent Liver Fat Content in a Healthy Normal BMI Population as Quantified by Fat-Water Separating DIXON MR Imaging. PLoS One (2015) 0.78
Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology. World J Gastroenterol (2015) 0.78
Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference. J Magn Reson Imaging (2015) 0.78
Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents. World J Gastroenterol (2016) 0.78
Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford) (2011) 0.78
Feasibility of and agreement between MR imaging and spectroscopic estimation of hepatic proton density fat fraction in children with known or suspected nonalcoholic fatty liver disease. Abdom Imaging (2015) 0.77
In vivo breath-hold (1) H MRS simultaneous estimation of liver proton density fat fraction, and T1 and T2 of water and fat, with a multi-TR, multi-TE sequence. J Magn Reson Imaging (2015) 0.77
Macroscopic heterogeneity of liver fat: an MR-based study in type-2 diabetic patients. Eur Radiol (2012) 0.77
Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI. J Magn Reson Imaging (2016) 0.77
Diagnostic value of MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. Biomed Res Int (2015) 0.77
Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom. Magn Reson Med (2016) 0.76
Quantitative Imaging Biomarkers of NAFLD. Dig Dis Sci (2016) 0.76
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol (2016) 0.76
Agreement between region-of-interest- and parametric map-based hepatic proton density fat fraction estimation in adults with chronic liver disease. Abdom Radiol (2016) 0.75
Quantification of liver fat in the presence of iron overload. J Magn Reson Imaging (2016) 0.75
Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients (2016) 0.75
Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study. NMR Biomed (2012) 0.75
Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods. J Med Life (2017) 0.75
Chemical shift MR imaging methods for the quantification of transcatheter lipiodol delivery to the liver: preclinical feasibility studies in a rodent model. Radiology (2012) 0.75
Reproducibility of Intra- and Inter-scanner Measurements of Liver Fat Using Complex Confounder-corrected Chemical Shift Encoded MRI at 3.0 Tesla. Sci Rep (2016) 0.75
Feasibility of a three-step magnetic resonance imaging approach for the assessment of hepatic steatosis in an asymptomatic study population. Eur Radiol (2015) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
Simple proton spectroscopic imaging. Radiology (1984) 7.30
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Improved method for accurate and efficient quantification of MRS data with use of prior knowledge J Magn Reson (1997) 6.84
Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol (1999) 5.38
Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes (2005) 5.22
AGA technical review on nonalcoholic fatty liver disease. Gastroenterology (2002) 4.61
Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging. Magn Reson Med (2005) 4.57
Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging (2008) 4.13
Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise. Magn Reson Med (2007) 3.88
Multiecho reconstruction for simultaneous water-fat decomposition and T2* estimation. J Magn Reson Imaging (2007) 3.79
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology (2004) 3.59
Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med (2001) 3.32
Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology (1998) 3.13
Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging (1995) 2.77
Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology (2005) 2.69
Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging (1997) 2.69
Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology (2007) 2.48
Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol (1999) 2.34
Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point dixon and three-point IDEAL. Magn Reson Med (2008) 2.27
Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging (1994) 2.27
Update on nonalcoholic fatty liver disease. J Clin Gastroenterol (2002) 2.20
Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol (2003) 2.01
Liver biopsy:complications and risk factors. World J Gastroenterol (1999) 1.91
A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2005) 1.86
Comparison of fat quantification methods: a phantom study at 3.0T. J Magn Reson Imaging (2008) 1.55
Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience. Radiology (2005) 1.48
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg (2005) 1.42
MR imaging of fat-containing tissues: valuation of two quantitative imaging techniques in comparison with localized proton spectroscopy. Magn Reson Imaging (1993) 1.41
Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis (2004) 1.35
Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol (2006) 1.33
Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy. Magn Reson Med (2006) 1.28
Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: a review. Liver Int (2008) 1.21
Treatment of nonalcoholic fatty liver disease. Ann Hepatol (2004) 1.14
Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol (2005) 1.13
Hepatic macrosteatosis: predicting appropriateness of liver donation by using MR imaging--correlation with histopathologic findings. Radiology (2006) 1.12
Non-invasive quantification of hepatic fat fraction by fast 1.0, 1.5 and 3.0 T MR imaging. Eur J Radiol (2007) 1.12
Assessment of the variations in fat content in normal liver using a fast MR imaging method in comparison with results obtained by spectroscopic imaging. Eur Radiol (2007) 1.04
Feasibility of quantitative intrahepatic lipid imaging applied to the magnetic resonance dual gradient echo sequence. Magn Reson Med Sci (2003) 0.98
Effects of intravenous gadolinium administration and flip angle on the assessment of liver fat signal fraction with opposed-phase and in-phase imaging. J Magn Reson Imaging (2008) 0.95
Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surg (2007) 0.92
Pharmacologic management of nonalcoholic fatty liver disease. Clin Liver Dis (2004) 0.85
Multi-exponential relaxation analysis with MR imaging and NMR spectroscopy using fat-water systems. Magn Reson Imaging (1987) 0.82
MR imaging of diffuse liver disease. Hepatic fat and iron. Magn Reson Imaging Clin N Am (1997) 0.82
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Prevalence of fatty liver in children and adolescents. Pediatrics (2006) 7.00
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. J Am Coll Cardiol (2004) 4.43
Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology (2005) 4.21
Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging (2008) 4.13
Magnetic resonance: an introduction to ultrashort TE (UTE) imaging. J Comput Assist Tomogr (2003) 3.63
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc (2004) 3.21
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol (2007) 3.17
Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology (2011) 3.08
In vivo characterization of the liver fat ¹H MR spectrum. NMR Biomed (2010) 3.07
Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr (2006) 3.03
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr (2003) 2.77
Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging (2011) 2.75
Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation (2008) 2.70
Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics (2005) 2.55
Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. Otol Neurotol (2004) 2.54
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology (2011) 2.42
CT and MR imaging of extrahepatic fatty masses of the abdomen and pelvis: techniques, diagnosis, differential diagnosis, and pitfalls. Radiographics (2005) 2.37
Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry (2005) 2.34
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology (2008) 2.33
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging (2011) 2.27
Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology (2006) 2.23
Fatty liver: imaging patterns and pitfalls. Radiographics (2006) 2.21
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging (2009) 2.18
Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques. Magn Reson Imaging (2011) 2.15
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol (2011) 2.15
Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology (2005) 2.14
Advances in pediatric nonalcoholic fatty liver disease. Hepatology (2009) 2.03
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology (2014) 2.00
Abdominal wall hernias: imaging features, complications, and diagnostic pitfalls at multi-detector row CT. Radiographics (2005) 1.98
Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr (2006) 1.97
Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology (2008) 1.92
Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc (2003) 1.91
Interventions to increase smoking cessation at the population level: how much progress has been made in the last two decades? Tob Control (2012) 1.90
Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging (2012) 1.90
Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr (2012) 1.82
SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology (2010) 1.81
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology (2013) 1.78
Prevalence and outcome of allergic colitis in healthy infants with rectal bleeding: a prospective cohort study. J Pediatr Gastroenterol Nutr (2005) 1.78
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology (2013) 1.77
Influence of race, ethnicity, and culture on childhood obesity: implications for prevention and treatment: a consensus statement of Shaping America's Health and the Obesity Society. Diabetes Care (2008) 1.74
Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol (2006) 1.74
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol (2010) 1.70
Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn Reson Med (2011) 1.67